Research programme: S-nitrosothiol modulating agents - Nivalis Therapeutics

Drug Profile

Research programme: S-nitrosothiol modulating agents - Nivalis Therapeutics

Alternative Names: GSNORi's - Nivalis Therapeutics; N 6547; N 91121; N 91138; N 91169; N6022 analogues; S nitrosoglutathione reductase inhibitors - Nivalis Therapeutics

Latest Information Update: 20 Feb 2015

Price : $50

At a glance

  • Originator NitroMed
  • Developer Nivalis Therapeutics
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators; Glutathione-independent formaldehyde dehydrogenase inhibitors; Nitric oxide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Cystic fibrosis; Inflammatory bowel diseases; Respiratory tract disorders

Most Recent Events

  • 23 Dec 2013 N30 Pharmaceuticals plans a phase I trial in Healthy volunteers in the USA (SNO2; NCT02013388)
  • 21 Mar 2013 Preclinical pharmacodynamics data from studies in Cystic fibrosis and Chronic obstructive pulmonary disease released by N30 Pharma
  • 01 Jan 2013 Preclinical trials in Inflammatory bowel disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top